Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
May 2023
Historique:
revised: 05 01 2023
received: 22 07 2022
accepted: 19 01 2023
medline: 18 5 2023
pubmed: 2 3 2023
entrez: 1 3 2023
Statut: ppublish

Résumé

Atrial fibrillation (AF) prevalence estimates vary and have been based on cohorts with clinically established or diagnosed disease. Undiagnosed AF prevalence estimates are less certain as they are based on nongeneralizable convenience samples. Because AF is often asymptomatic, it my remain undiagnosed until the development of complications such as stroke or heart failure. Consequently, the observed prevalence of diagnosed AF from the literature may underestimate total disease burden. We therefore sought to estimate the total prevalence of both diagnosed and undiagnosed AF. We performed a retrospective cohort study from 2012 to 2017 using data from five US medical claims data sets. Undiagnosed AF prevalence was estimated based on the observed incidence of ischemic stroke, systemic embolism (SE), and AF incidence after a stroke/SE. The diagnosed AF cohort included AF patients between Q1 2014 and Q3 2015. The undiagnosed AF cohort were patients with assumed undiagnosed AF in the year before a stroke/SE and who were newly diagnosed with AF in the 3-month poststroke/SE. Stroke/SE incidence was calculated among all AF patients and the ratio of number of undiagnosed AF patients to stroke rate was created. Age- and sex-adjusted estimates were stratified by period of assumed undiagnosed AF before poststroke/SE AF diagnosis (1 or 2 years). The estimated US prevalence of AF (diagnosed and undiagnosed) in Q3 2015 was 5 628 000 cases, of which 591 000 cases (11%) were undiagnosed. The assumed 2-year undiagnosed AF prevalence was 23% (1 531 000) of the total prevalent patients with AF (6 568 000). Undiagnosed (vs. diagnosed) AF patients were older and had higher CHA2DS2-VASc scores. Of undiagnosed AF, 93% had CHA2DS2-VASc ≥2 and met OAC criteria. These contemporary estimates demonstrate the high prevalence of undiagnosed AF in the United States. Undiagnosed AF patients are composed of primarily elderly individuals who if diagnosed, would meet criteria for stroke prevention therapy.

Sections du résumé

BACKGROUND BACKGROUND
Atrial fibrillation (AF) prevalence estimates vary and have been based on cohorts with clinically established or diagnosed disease. Undiagnosed AF prevalence estimates are less certain as they are based on nongeneralizable convenience samples.
HYPOTHESIS OBJECTIVE
Because AF is often asymptomatic, it my remain undiagnosed until the development of complications such as stroke or heart failure. Consequently, the observed prevalence of diagnosed AF from the literature may underestimate total disease burden. We therefore sought to estimate the total prevalence of both diagnosed and undiagnosed AF.
METHODS METHODS
We performed a retrospective cohort study from 2012 to 2017 using data from five US medical claims data sets. Undiagnosed AF prevalence was estimated based on the observed incidence of ischemic stroke, systemic embolism (SE), and AF incidence after a stroke/SE. The diagnosed AF cohort included AF patients between Q1 2014 and Q3 2015. The undiagnosed AF cohort were patients with assumed undiagnosed AF in the year before a stroke/SE and who were newly diagnosed with AF in the 3-month poststroke/SE. Stroke/SE incidence was calculated among all AF patients and the ratio of number of undiagnosed AF patients to stroke rate was created. Age- and sex-adjusted estimates were stratified by period of assumed undiagnosed AF before poststroke/SE AF diagnosis (1 or 2 years).
RESULTS RESULTS
The estimated US prevalence of AF (diagnosed and undiagnosed) in Q3 2015 was 5 628 000 cases, of which 591 000 cases (11%) were undiagnosed. The assumed 2-year undiagnosed AF prevalence was 23% (1 531 000) of the total prevalent patients with AF (6 568 000). Undiagnosed (vs. diagnosed) AF patients were older and had higher CHA2DS2-VASc scores. Of undiagnosed AF, 93% had CHA2DS2-VASc ≥2 and met OAC criteria.
CONCLUSIONS CONCLUSIONS
These contemporary estimates demonstrate the high prevalence of undiagnosed AF in the United States. Undiagnosed AF patients are composed of primarily elderly individuals who if diagnosed, would meet criteria for stroke prevention therapy.

Identifiants

pubmed: 36855960
doi: 10.1002/clc.23983
pmc: PMC10189075
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

484-493

Subventions

Organisme : Bristol-Myers Squibb
Organisme : Pfizer

Informations de copyright

© 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

Références

Am J Cardiol. 2015 Sep 1;116(5):733-9
pubmed: 26138378
Stroke. 2002 Oct;33(10):2465-70
pubmed: 12364739
Am J Cardiol. 2017 Dec 1;120(11):1961-1965
pubmed: 29033050
Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):85-93
pubmed: 22235070
Thromb Haemost. 2017 Jun 2;117(6):1072-1082
pubmed: 28300870
Popul Health Manag. 2014 Jun;17(3):159-65
pubmed: 24476557
Europace. 2013 May;15(5):657-62
pubmed: 23258819
Circulation. 2008 May 20;117(20):e340-3
pubmed: 18490529
Circulation. 2017 May 9;135(19):1851-1867
pubmed: 28483832
Am J Cardiol. 2013 Oct 15;112(8):1142-7
pubmed: 23831166
Heart. 2004 Mar;90(3):239-40
pubmed: 14966028
J Am Heart Assoc. 2016 Nov 14;5(11):
pubmed: 27930356
J Health Serv Res Policy. 2019 Jul;24(3):172-181
pubmed: 31291765
PLoS One. 2018 Apr 12;13(4):e0195088
pubmed: 29649277
Clin Cardiol. 2023 May;46(5):484-493
pubmed: 36855960
Circulation. 2020 May 12;141(19):1523-1526
pubmed: 32392102
Thromb Haemost. 2014 Jun;111(6):1167-76
pubmed: 24687081
Eur Heart J. 2020 Mar 7;41(10):1075-1085
pubmed: 31811716
JAMA Cardiol. 2021 May 1;6(5):558-567
pubmed: 33625468
Circulation. 2009 May 12;119(18):2516-25
pubmed: 19433768
Am J Med. 2015 Mar;128(3):260-7.e1
pubmed: 25446299
Circ Res. 2020 Jun 19;127(1):4-20
pubmed: 32716709
Circulation. 2021 Jan 26;143(4):372-388
pubmed: 33493033
Pituitary. 2014 Aug;17(4):333-41
pubmed: 24037646
Rev Esp Cardiol (Engl Ed). 2013 Jul;66(7):545-52
pubmed: 24776203
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):991-5
pubmed: 22349706
Arrhythm Electrophysiol Rev. 2018 Mar;7(1):39-42
pubmed: 29636971
BMJ. 2007 Aug 25;335(7616):383
pubmed: 17673732
Stroke. 2021 Jul;52(7):e364-e467
pubmed: 34024117
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
J Atr Fibrillation. 2012 Oct 06;5(3):649
pubmed: 28496776
Stroke. 2018 Dec;49(12):2933-2944
pubmed: 30571400

Auteurs

Mintu P Turakhia (MP)

Stanford University School of Medicine, Stanford, California, USA.

Jennifer D Guo (JD)

Bristol Myers Squibb, Lawrenceville, New Jersey, USA.

Allison Keshishian (A)

STATinMED, LLC, Dallas, Texas, USA.

Rachel Delinger (R)

STATinMED, LLC, Dallas, Texas, USA.

Xiaoxi Sun (X)

STATinMED, LLC, Dallas, Texas, USA.

Mauricio Ferri (M)

Bristol Myers Squibb, Lawrenceville, New Jersey, USA.

Cristina Russ (C)

Pfizer, New York City, New York, USA.

Matthew Cato (M)

Pfizer, New York City, New York, USA.

Huseyin Yuce (H)

New York City College of Technology, City University of New York, New York City, New York, USA.

Patrick Hlavacek (P)

Pfizer, New York City, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH